Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
A live webcast of the fireside chat may be accessed on the Investors page of the company's website at , where a replay of the events will also be available for a limited time.CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.
马萨诸塞州剑桥，2024年11月26日 /PRNewswire/ -- leap therapeutics, Inc. (纳斯达克：LPTX)，一家专注于开发靶向和免疫肿瘤治疗的生物技术公司，今日宣布，总裁兼首席执行官Douglas E. Onsi将参加在纽约市派杰投资第36届年度医疗保健大会上的炉边聊天。
Leap Presentation Details:
Leap演讲详情：
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 4:00 p.m. Eastern Time
派杰投资第36届医疗保健年会
日期：2024年12月4日星期三
时间：东部时间下午4:00
A live webcast of the fireside chat may be accessed on the Investors page of the company's website at , where a replay of the events will also be available for a limited time.
炉边聊天的直播网络广播可以在公司网站的投资者页面访问，活动的重播也将在有限时间内提供。
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via .
关于Leap Therapeutics
leap therapeutics（纳斯达克：LPTX）专注于开发靶向和免疫肿瘤治疗。Leap最先进的临床候选药物DKN-01是一种人源化单克隆抗体，靶向Dickkopf-1（DKK1）蛋白。DKN-01正在针对食管胃肠道癌、结直肠癌和妇科癌症的患者进行开发。Leap的管线还包括FL-501，这是一种靶向生长和分化因子15（GDF-15）蛋白的人源化单克隆抗体，正在进行临床前开发。有关leap therapeutics的更多信息，请访问或查看我们向SEC提交的公共备案文件，这些文件可以通过EDGAR访问，网址为http://www.sec.gov或通过其他途径。
CONTACT:
联系人：
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
[email protected]
Douglas E. Onsi
董事长兼首席执行官
Leap Therapeutics, Inc.
617-714-0360
[email protected]
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
[email protected]
Matthew DeYoung
投资者关系
阿哥特合伙人。
212-600-1902
[email protected]
SOURCE Leap Therapeutics, Inc.
来源 leap therapeutics, Inc.
